Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
or

Chromadex Corp CS (CDXC)

Chromadex Corp CS (CDXC)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
7.87 -0.07 (-0.88%) 03/18/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 7.87 unch (unch) -
Quote Overview for Tue, Mar 18th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
7.75
Day High
7.92
Open 7.91
Previous Close 7.94 7.94
Volume 554,800 554,800
Avg Vol 1,676,165 1,676,165
Stochastic %K 66.88% 66.88%
Weighted Alpha +49.26 +49.26
5-Day Change -0.03 (-0.38%) -0.03 (-0.38%)
52-Week Range 2.31 - 9.18 2.31 - 9.18
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 611,893
  • Shares Outstanding, K 77,750
  • Annual Sales, $ 99,600 K
  • Annual Income, $ 8,550 K
  • EBIT $ 8 M
  • EBITDA $ 9 M
  • 60-Month Beta 2.21
  • Price/Sales 6.20
  • Price/Cash Flow 133.05
  • Price/Book 13.04
  • Price/Earnings ttm 198.50
  • Earnings Per Share ttm 0.04
  • Most Recent Earnings $0.03 on 03/04/25
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.01
  • Number of Estimates 2
  • High Estimate 0.03
  • Low Estimate 0.00
  • Prior Year -0.01
  • Growth Rate Est. (year over year) +200.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.25 +49.90%
on 02/24/25
Period Open: 5.91
9.18 -14.27%
on 03/05/25
+1.96 (+33.16%)
since 02/18/25
3-Month
5.16 +52.52%
on 01/07/25
Period Open: 5.70
9.18 -14.27%
on 03/05/25
+2.17 (+38.07%)
since 12/18/24
52-Week
2.31 +241.43%
on 06/26/24
Period Open: 2.99
9.18 -14.27%
on 03/05/25
+4.88 (+163.21%)
since 03/18/24

Most Recent Stories

More News
Investors Hit the Jackpot! 8 Micro, Small, and Mid-Cap Stocks That Went Through the Roof

The broader stock market faced renewed selling pressure today, with major indices experiencing sharp declines. The Dow Jones Industrial Average plunged 500 points, extending its recent losing streak as...

CDXC : 7.87 (-0.88%)
MP : 22.89 (+0.18%)
PRTS : 0.9012 (+7.93%)
TNXP : 17.02 (+13.77%)
SITM : 137.74 (+5.62%)
ARBB : 0.6800 (-2.86%)
CMRX : 8.54 (-0.12%)
GV : 1.9300 (-1.03%)
ChromaDex: Q4 Earnings Snapshot

ChromaDex: Q4 Earnings Snapshot

CDXC : 7.87 (-0.88%)
Pick These 4 Stocks With Solid Net Profit Margin to Boost Return

Investors prefer to invest in businesses that reap profits on a regular basis. To gauge the extent of profits, there is no better metric than net profit margin.A higher net margin reflects a company’s...

CHX : 24.59 (-1.56%)
CDXC : 7.87 (-0.88%)
GFF : 65.88 (-0.23%)
BGC : 8.74 (+1.39%)
The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex

For Immediate ReleaseChicago, IL – December 26, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and...

CDXC : 7.87 (-0.88%)
ADMA : 21.73 (+1.59%)
TARS : 50.00 (+1.13%)
STOK : 9.52 (+3.25%)
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow

The biotech sector witnessed a see-saw performance in 2024. While the year started on a positive note, much of the gains slowed down in the second half of 2024. The downside in the second half was due...

CDXC : 7.87 (-0.88%)
ADMA : 21.73 (+1.59%)
TARS : 50.00 (+1.13%)
STOK : 9.52 (+3.25%)
Insider Sale: Director at $CDXC (CDXC) Sells 37,161 Shares

Frank L Jr Jaksch, a director at $CDXC ($CDXC), sold 37,161 shares of the company on 12-13-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 13.2% of their...

CDXC : 7.87 (-0.88%)
Insider Purchase: Chief Financial Officer of $CDXC (CDXC) Buys 2,907 Shares

Ozan Pamir, the Chief Financial Officer of $CDXC ($CDXC), bought 2,907 shares of the company on 11-22-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased...

CDXC : 7.87 (-0.88%)
5 Stocks With Recent Price Strength to Tap Wall Street Rally

U.S. stock markets started November, adding more steam to the ongoing rally. The primary reason was the anticipation of Donald Trump becoming the 47th president of the country. On Nov 5, Trump clinched...

CORT : 69.27 (+7.10%)
SEZL : 42.84 (+3.83%)
CDXC : 7.87 (-0.88%)
TILE : 18.27 (+0.55%)
BGC : 8.74 (+1.39%)
ChromaDex to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023

ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, May 10, 2023 at 4:30 p.m. ET to discuss...

CDXC : 7.87 (-0.88%)
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2022 Results

ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2022 financial results.

CDXC : 7.87 (-0.88%)
ChromaDex to Participate at the 35th Annual ROTH Capital Partners Conference on March 13, 2023

ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, today announced that senior management will participate at the 35 th annual ROTH Capital Partners...

CDXC : 7.87 (-0.88%)
ChromaDex to Report Fourth Quarter and Fiscal Year 2022 Financial Results on Wednesday, March 8, 2023

ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 8, 2023 at 4:30 p.m. ET to...

CDXC : 7.87 (-0.88%)
ChromaDex Announces Issuance of New U.S. Patent on Dihydronicotinamide Riboside (NRH) and Dihydronicotinic Acid Riboside (NARH), Further Solidifying ChromaDex as the Leader in the Nicotinamide Adenine Dinucleotide (NAD+) Precursor Space

ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, holds an exclusive license from Queen’s University Belfast for methods of making nicotinamide riboside (NR) and...

CDXC : 7.87 (-0.88%)
A Letter from the ChromaDex Chief Executive Officer

The following is issued on behalf of ChromaDex (NASDAQ: CDXC).

CDXC : 7.87 (-0.88%)
ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs), Featuring Nicotinamide Riboside (NR), Improved Cognitive Functions in Alzheimer's Disease (AD) Patients

ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced promising findings from a first-of-its kind clinical study, as reported in the peer-reviewed journal Translational...

CDXC : 7.87 (-0.88%)
ChromaDex Shares Promising Findings from First-Of-Its Kind Clinical Study to Demonstrate Oral Nicotinamide Riboside (NR) Supplementation Increases Muscle Mitochondrial Biogenesis

ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced promising findings from a first-of-its kind five-month-long clinical study, as reported in the peer-reviewed...

CDXC : 7.87 (-0.88%)
ChromaDex Appoints Leading Aging and Neurodegenerative Disease Researcher, Dr. Vilhelm Bohr, to its Scientific Advisory Board (SAB)

ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced it has appointed Dr. Vilhelm (Will) Bohr, M.D., Ph.D., D.Sc. to its Scientific Advisory Board (SAB). Dr....

CDXC : 7.87 (-0.88%)
ChromaDex Named Brianna Gerber Chief Financial Officer

ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced that it has appointed Brianna Gerber to the role of Chief Financial Officer, effective January 1, 2023....

CDXC : 7.87 (-0.88%)
ChromaDex Shares Promising Findings from Clinical Study Demonstrating Oral Supplementation with Nicotinamide Riboside (NR) Increased Nicotinamide Adenine Dinucleotide (NAD+) Levels in the Brain and Positively Impacted Neurodegenerative Biomarkers

ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced promising new findings based on a previously published clinical trial of company’s proprietary Niagen...

CDXC : 7.87 (-0.88%)
ChromaDex Reports FDA’s Conclusion that Nicotinamide Mononucleotide (NMN) May Not Be Sold or Marketed as a Dietary Supplement in the United States

ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, today announced that on November 4, 2022, the U.S. FDA declared nicotinamide mononucleotide (NMN) may no longer be...

CDXC : 7.87 (-0.88%)

Business Summary

ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex's core business strategy is...

See More

Key Turning Points

3rd Resistance Point 8.12
2nd Resistance Point 8.02
1st Resistance Point 7.95
Last Price 7.87
1st Support Level 7.77
2nd Support Level 7.67
3rd Support Level 7.59

See More

52-Week High 9.18
Last Price 7.87
Fibonacci 61.8% 6.55
Fibonacci 50% 5.74
Fibonacci 38.2% 4.93
52-Week Low 2.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.